Among patients with advanced melanoma, median overall survival was 72 months with nivolumab plus ipilimumab and was 37 months with nivolumab alone, as compared with 20 months with ipilimumab alone. Full CheckMate 067 trial results: nej.md/4dUqm0g
#MedSky
#MedSky
January 5, 2025 at 5:11 PM
Among patients with advanced melanoma, median overall survival was 72 months with nivolumab plus ipilimumab and was 37 months with nivolumab alone, as compared with 20 months with ipilimumab alone. Full CheckMate 067 trial results: nej.md/4dUqm0g
#MedSky
#MedSky
with the vaccine. While patients typically experienced flu-like symptoms for one to two days after their vaccinations, NONE experienced severe side effects. There were also no significant differences in outcomes between patients who received ipilimumab after vaccination and those who received the
February 26, 2025 at 5:06 PM
with the vaccine. While patients typically experienced flu-like symptoms for one to two days after their vaccinations, NONE experienced severe side effects. There were also no significant differences in outcomes between patients who received ipilimumab after vaccination and those who received the
personalized cancer vaccine. Four patients received just the vaccine and five others also received small doses of the immunotherapy drug ipilimumab. The results? ALL nine patients had an immune response within a three-week period and cancer-fighting T-cells remained elevated for the duration of the
February 26, 2025 at 5:05 PM
personalized cancer vaccine. Four patients received just the vaccine and five others also received small doses of the immunotherapy drug ipilimumab. The results? ALL nine patients had an immune response within a three-week period and cancer-fighting T-cells remained elevated for the duration of the
Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer | NEJM
Patients with microsatellite-instability–high (MSI-H) or mismatch-repair–deficient (dMMR) metastatic colorectal cancer have poor outcomes with standard chemotherapy with or without targeted therapi...
www.nejm.org
November 28, 2024 at 4:01 AM
Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
Ipilimumab sind aus der Behandlung vieler Krebserkrankungen wie dem schwarzen Hautkrebs oder dem Lungenkrebs seit 2016 nicht mehr wegzudenken.
Insgesamt sind über 30 monoklonale Antikörper in der Onkologie zugelassen und werden täglich im Alltag auch eingesetzt.
Ende.
Insgesamt sind über 30 monoklonale Antikörper in der Onkologie zugelassen und werden täglich im Alltag auch eingesetzt.
Ende.
January 8, 2025 at 6:27 AM
Ipilimumab sind aus der Behandlung vieler Krebserkrankungen wie dem schwarzen Hautkrebs oder dem Lungenkrebs seit 2016 nicht mehr wegzudenken.
Insgesamt sind über 30 monoklonale Antikörper in der Onkologie zugelassen und werden täglich im Alltag auch eingesetzt.
Ende.
Insgesamt sind über 30 monoklonale Antikörper in der Onkologie zugelassen und werden täglich im Alltag auch eingesetzt.
Ende.
Nivolumab plus ipilimumab in metastatic variant histology renal cell carcinoma - Mohammad Jad Moussa
@mjmoussa.bsky.social
oncodaily.com/science/moha...
#Cancer #CancerResearch #Medicine #Health #RenalCellCarcinoma #KidneyCancer #Oncology #OncoDaily
@mjmoussa.bsky.social
oncodaily.com/science/moha...
#Cancer #CancerResearch #Medicine #Health #RenalCellCarcinoma #KidneyCancer #Oncology #OncoDaily
Mohammad Jad Moussa: Nivolumab plus ipilimumab in metastatic variant histology renal cell carcinoma - OncoDaily
Mohammad Jad Moussa: Nivolumab plus ipilimumab in metastatic variant histology renal cell carcinoma / cancer, ipilimumab, Jaanki Khandelwal, Journal for
oncodaily.com
March 2, 2025 at 6:59 PM
Nivolumab plus ipilimumab in metastatic variant histology renal cell carcinoma - Mohammad Jad Moussa
@mjmoussa.bsky.social
oncodaily.com/science/moha...
#Cancer #CancerResearch #Medicine #Health #RenalCellCarcinoma #KidneyCancer #Oncology #OncoDaily
@mjmoussa.bsky.social
oncodaily.com/science/moha...
#Cancer #CancerResearch #Medicine #Health #RenalCellCarcinoma #KidneyCancer #Oncology #OncoDaily
Checkpoint inhibitors really have revolutionised care of advanced melanoma - 10 year survival data: 🩺👇
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma | NEJM
Previous results from this trial showed longer overall survival after treatment with
nivolumab plus ipilimumab or with nivolumab monotherapy than with ipilimumab monotherapy
in patients with advanc...
www.nejm.org
September 19, 2024 at 10:42 AM
Checkpoint inhibitors really have revolutionised care of advanced melanoma - 10 year survival data: 🩺👇
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
Ahead of #WorldCancerDay, a new study reports results from the interim analysis of progression-free survival for nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer.
Explore the findings ➡️ tinyurl.com/ye2bx6bd
Explore the findings ➡️ tinyurl.com/ye2bx6bd
February 3, 2025 at 12:06 PM
Ahead of #WorldCancerDay, a new study reports results from the interim analysis of progression-free survival for nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer.
Explore the findings ➡️ tinyurl.com/ye2bx6bd
Explore the findings ➡️ tinyurl.com/ye2bx6bd
So proud of this aussie trial - changed practice. @melanomaau.bsky.social @sydneyuni.bsky.social
@science.org.au
Ipilimumab + nivolumab vs nivolumab in patients with #melanoma brain metastases (ABC): 7-yr follow-up of randomised, ph 2 study - The Lancet Oncology www.thelancet.com/journals/lan...
@science.org.au
Ipilimumab + nivolumab vs nivolumab in patients with #melanoma brain metastases (ABC): 7-yr follow-up of randomised, ph 2 study - The Lancet Oncology www.thelancet.com/journals/lan...
Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study
Our findings suggest that ipilimumab plus nivolumab maintains efficacy to at least
7 years in patients with active asymptomatic brain metastasis. Upfront ipilimumab
plus nivolumab should be the standa...
www.thelancet.com
February 18, 2025 at 12:28 PM
So proud of this aussie trial - changed practice. @melanomaau.bsky.social @sydneyuni.bsky.social
@science.org.au
Ipilimumab + nivolumab vs nivolumab in patients with #melanoma brain metastases (ABC): 7-yr follow-up of randomised, ph 2 study - The Lancet Oncology www.thelancet.com/journals/lan...
@science.org.au
Ipilimumab + nivolumab vs nivolumab in patients with #melanoma brain metastases (ABC): 7-yr follow-up of randomised, ph 2 study - The Lancet Oncology www.thelancet.com/journals/lan...
An extraordinary result for ipilimumab immunotherapy given as a first line therapy for glioblastoma
share.google/485XFZxmBm26...
share.google/485XFZxmBm26...
Dad’s aggressive brain cancer vanishes after taking new drug
The NHS is now looking for patients with glioblastoma to take part in a new drug trial
share.google
November 1, 2025 at 9:18 AM
An extraordinary result for ipilimumab immunotherapy given as a first line therapy for glioblastoma
share.google/485XFZxmBm26...
share.google/485XFZxmBm26...
Wonderful results: The combination of nivolumab and ipilimumab in patients with metastatic colorectal cancer led to 24-month progression-free survival of 72%, as compared with 14% with chemotherapy: nej.md/4eGp1tj
Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer | NEJM
Patients with microsatellite-instability–high (MSI-H) or mismatch-repair–deficient (dMMR) metastatic colorectal cancer have poor outcomes with standard chemotherapy with or without targeted therapi...
nej.md
November 29, 2024 at 4:02 AM
Wonderful results: The combination of nivolumab and ipilimumab in patients with metastatic colorectal cancer led to 24-month progression-free survival of 72%, as compared with 14% with chemotherapy: nej.md/4eGp1tj
in the setting of cancer, which maintains an immunosuppressive tumor microenvironment to prevent elimination by the immune system. We now have antibodies against CTLA-4 used for cancer treatment (immune checkpoint inhibitors):
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | NEJM
An improvement in overall survival among patients with metastatic melanoma has been
an elusive goal. In this phase 3 study, ipilimumab — which blocks cytotoxic T-lymphocyte–associated
antigen 4 to ...
www.nejm.org
October 6, 2025 at 1:04 PM
in the setting of cancer, which maintains an immunosuppressive tumor microenvironment to prevent elimination by the immune system. We now have antibodies against CTLA-4 used for cancer treatment (immune checkpoint inhibitors):
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
𝟭. 𝗣𝗲𝗲𝗿-𝗿𝗲𝘃𝗶𝗲𝘄𝗲𝗱 𝗼𝗿𝗶𝗴𝗶𝗻𝗮𝗹 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵. Whether late breaking trials from a major scientific meeting or studies found in our Weekly Table of Contents, you'll find important results here.
📊 Chart: Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer nej.md/4eGp1tj
📊 Chart: Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer nej.md/4eGp1tj
December 6, 2024 at 8:24 PM
𝟭. 𝗣𝗲𝗲𝗿-𝗿𝗲𝘃𝗶𝗲𝘄𝗲𝗱 𝗼𝗿𝗶𝗴𝗶𝗻𝗮𝗹 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵. Whether late breaking trials from a major scientific meeting or studies found in our Weekly Table of Contents, you'll find important results here.
📊 Chart: Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer nej.md/4eGp1tj
📊 Chart: Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer nej.md/4eGp1tj
The more potent and bespoke immunotherapy vs cancer, the better. Today's example is a neoantigen vaccine vs melanoma
cell.com/cell/fulltex...
cell.com/cell/fulltex...
A multi-adjuvant personal neoantigen vaccine generates potent immunity in melanoma
A personalized neoantigen peptide vaccine formulated with Montanide plus poly-ICLC
and administered with local ipilimumab plus systemic nivolumab induces robust neoepitope-specific
T cell responses an...
cell.com
July 10, 2025 at 3:17 PM
The more potent and bespoke immunotherapy vs cancer, the better. Today's example is a neoantigen vaccine vs melanoma
cell.com/cell/fulltex...
cell.com/cell/fulltex...
FDA Approves Nivolumab and Ipilimumab for First-Line Treatment of Unresectable Hepatocellular Carcinoma Based on CheckMate-9DW Trial
@fda.gov
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #FDA #Nivolumab #Ipilimumab #HepatocellularCarcinoma
@fda.gov
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #FDA #Nivolumab #Ipilimumab #HepatocellularCarcinoma
FDA Approves Nivolumab and Ipilimumab for First-Line Treatment of Unresectable Hepatocellular Carcinoma Based on CheckMate-9DW Trial - OncoDaily
FDA approves nivolumab and ipilimumab as first-line therapy for unresectable HCC, based on CheckMate-9DW trial results.
oncodaily.com
April 13, 2025 at 9:23 PM
FDA Approves Nivolumab and Ipilimumab for First-Line Treatment of Unresectable Hepatocellular Carcinoma Based on CheckMate-9DW Trial
@fda.gov
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #FDA #Nivolumab #Ipilimumab #HepatocellularCarcinoma
@fda.gov
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #FDA #Nivolumab #Ipilimumab #HepatocellularCarcinoma
FDA Approves Nivolumab and Ipilimumab for Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer: CheckMate 8HW trial results
@fda.gov
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ColonCancer #ColorectalCancer #CRC #dMMR #FDAapproval
@fda.gov
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ColonCancer #ColorectalCancer #CRC #dMMR #FDAapproval
Ipilimumab and Nivolumab for dMMR/MSI-H Colorectal Cancer
Ipilimumab and Nivolumab approved for MSI-H/dMMR metastatic colorectal cancer. Learn about the CheckMate 8HW trial results.
oncodaily.com
April 10, 2025 at 9:22 PM
FDA Approves Nivolumab and Ipilimumab for Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer: CheckMate 8HW trial results
@fda.gov
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ColonCancer #ColorectalCancer #CRC #dMMR #FDAapproval
@fda.gov
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ColonCancer #ColorectalCancer #CRC #dMMR #FDAapproval
Ameliyat öncesinde iki immünoterapi ilacı olan nivolumab ve ipilimumab kombinasyonu.
September 12, 2025 at 12:48 PM
Ameliyat öncesinde iki immünoterapi ilacı olan nivolumab ve ipilimumab kombinasyonu.
Eine bahnbrechende Studie der Universitätsmedizin Mainz zeigt, dass die Kombination von Nivolumab und Ipilimumab die Überlebenschancen bei fortgeschrittenem Leberzellkarzinom signifikant verbessert.
www.mimikama.org/therapie-ino...
www.mimikama.org/therapie-ino...
Inoperable Lebertumoren: Neue Therapieformen aus Mainz
Neue Therapieoptionen für inoperable Lebertumore: Studie zeigt vielversprechende Ergebnisse mit Checkpoint-Inhibitoren.
www.mimikama.org
June 13, 2024 at 7:26 AM
Eine bahnbrechende Studie der Universitätsmedizin Mainz zeigt, dass die Kombination von Nivolumab und Ipilimumab die Überlebenschancen bei fortgeschrittenem Leberzellkarzinom signifikant verbessert.
www.mimikama.org/therapie-ino...
www.mimikama.org/therapie-ino...
Nivolumab plus ipilimumab significantly improves survival in advanced melanoma patients compared to ipilimumab alone over a decade.
by Wolchok JD, Chiarion-Sileni V (...) Medina T et 10 al. in N Engl J Med #MedSky
📖 read the article: https://www.nejm.org/doi/10.1056/NEJMoa2407417
by Wolchok JD, Chiarion-Sileni V (...) Medina T et 10 al. in N Engl J Med #MedSky
📖 read the article: https://www.nejm.org/doi/10.1056/NEJMoa2407417
January 11, 2025 at 8:27 PM
Nivolumab plus ipilimumab significantly improves survival in advanced melanoma patients compared to ipilimumab alone over a decade.
by Wolchok JD, Chiarion-Sileni V (...) Medina T et 10 al. in N Engl J Med #MedSky
📖 read the article: https://www.nejm.org/doi/10.1056/NEJMoa2407417
by Wolchok JD, Chiarion-Sileni V (...) Medina T et 10 al. in N Engl J Med #MedSky
📖 read the article: https://www.nejm.org/doi/10.1056/NEJMoa2407417
Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial
www.thelancet.com/journals/lan...
@thelancet.bsky.social
#GastroSky #MedSky #ASCOGI #OncSky @oncoalert.bsky.social
www.thelancet.com/journals/lan...
@thelancet.bsky.social
#GastroSky #MedSky #ASCOGI #OncSky @oncoalert.bsky.social
January 26, 2025 at 9:47 AM
Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial
www.thelancet.com/journals/lan...
@thelancet.bsky.social
#GastroSky #MedSky #ASCOGI #OncSky @oncoalert.bsky.social
www.thelancet.com/journals/lan...
@thelancet.bsky.social
#GastroSky #MedSky #ASCOGI #OncSky @oncoalert.bsky.social
New Paper Alert: NO LIMIT Trial. First-Line Nivolumab Plus Low-Dose Ipilimumab in MSI-High Advanced Gastric and GEJ Cancer
oncodaily.com/opinion/nivo...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #NOLIMIT #Nivolumab #Ipilimumab #GEJCancer #GastricCancer
oncodaily.com/opinion/nivo...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #NOLIMIT #Nivolumab #Ipilimumab #GEJCancer #GastricCancer
No Limit trial: Results of Nivolumab+Ipilmumab in MSI-H GC
Explore NO LIMIT trial's response rate with nivolumab plus low-dose ipilimumab in MSI-H advanced gastric cancer, showing durable clinical benefit.
oncodaily.com
May 19, 2025 at 8:18 PM
New Paper Alert: NO LIMIT Trial. First-Line Nivolumab Plus Low-Dose Ipilimumab in MSI-High Advanced Gastric and GEJ Cancer
oncodaily.com/opinion/nivo...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #NOLIMIT #Nivolumab #Ipilimumab #GEJCancer #GastricCancer
oncodaily.com/opinion/nivo...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #NOLIMIT #Nivolumab #Ipilimumab #GEJCancer #GastricCancer
Dr. Jason Luke’s Journey in Immuno-Oncology Innovation
oncodaily.com/dialogues/jo...
#AntiCTLA4 #Cancer #Immunotherapy #Ipilimumab #Melanoma #OncoDaily #Oncology #Medicine #Health
oncodaily.com/dialogues/jo...
#AntiCTLA4 #Cancer #Immunotherapy #Ipilimumab #Melanoma #OncoDaily #Oncology #Medicine #Health
Dr. Jason Luke's Journey in Immuno-Oncology Innovation - OncoDaily
Dr. Jason Luke's Journey in Immuno-Oncology Innovation / anti-CTLA-4, cancer, immunotherapy, ipilimumab, Jason J Luke, Melanoma, OncoDaily, Oncology, Ravi Kara
oncodaily.com
December 27, 2024 at 4:38 PM
Dr. Jason Luke’s Journey in Immuno-Oncology Innovation
oncodaily.com/dialogues/jo...
#AntiCTLA4 #Cancer #Immunotherapy #Ipilimumab #Melanoma #OncoDaily #Oncology #Medicine #Health
oncodaily.com/dialogues/jo...
#AntiCTLA4 #Cancer #Immunotherapy #Ipilimumab #Melanoma #OncoDaily #Oncology #Medicine #Health
Congrats to Yelena Janjigian and team on their study in @naturemedicine.bsky.social, which presented biomarker analysis of nivolumab plus chemotherapy or ipilimumab in #gastroesophagealcancer. @mskcancercenter.bsky.social
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial - Nature Medicine
Exploratory biomarker analyses of the phase 3 CheckMate 649 trial show that in patients with advanced gastroesophageal cancer, KRAS alterations were associated with greater overall survival (OS) benef...
www.nature.com
March 14, 2025 at 7:58 PM
Congrats to Yelena Janjigian and team on their study in @naturemedicine.bsky.social, which presented biomarker analysis of nivolumab plus chemotherapy or ipilimumab in #gastroesophagealcancer. @mskcancercenter.bsky.social
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Adding #radiotherapy (RT) to ipilimumab improves survival and disease control in #melanoma brain metastases, according to a new meta-analysis. #BrainMetastases #Immunotherapy #MetaAnalysis #Oncology link.springer.com/article/10.1...
The clinical benefit of adding radiotherapy to ipilimumab in patients with melanoma brain metastasis: a systematic review and meta-analysis - Clinical & Experimental Metastasis
Combining radiotherapy (RT) with Ipilimumab, a CTLA-4 inhibitor, holds promise in treating metastatic brain melanoma (MBM). Despite promising preclinical evidence, clinical studies evaluating their co...
link.springer.com
December 6, 2025 at 5:23 AM
Adding #radiotherapy (RT) to ipilimumab improves survival and disease control in #melanoma brain metastases, according to a new meta-analysis. #BrainMetastases #Immunotherapy #MetaAnalysis #Oncology link.springer.com/article/10.1...
Happy New Year! 🎆 Here’s a preview of the first issue of 2025:
Nivolumab plus Ipilimumab in Advanced Melanoma (CheckMate 067) nej.md/4dUqm0g
Asundexian vs. Apixaban in Atrial Fibrillation (OCEANIC-AF) nej.md/473TRdc
Vutrisiran in ATTR Amyloidosis with Cardiomyopathy (HELIOS-B) nej.md/48OTgx4
Nivolumab plus Ipilimumab in Advanced Melanoma (CheckMate 067) nej.md/4dUqm0g
Asundexian vs. Apixaban in Atrial Fibrillation (OCEANIC-AF) nej.md/473TRdc
Vutrisiran in ATTR Amyloidosis with Cardiomyopathy (HELIOS-B) nej.md/48OTgx4
January 2, 2025 at 1:42 PM
Happy New Year! 🎆 Here’s a preview of the first issue of 2025:
Nivolumab plus Ipilimumab in Advanced Melanoma (CheckMate 067) nej.md/4dUqm0g
Asundexian vs. Apixaban in Atrial Fibrillation (OCEANIC-AF) nej.md/473TRdc
Vutrisiran in ATTR Amyloidosis with Cardiomyopathy (HELIOS-B) nej.md/48OTgx4
Nivolumab plus Ipilimumab in Advanced Melanoma (CheckMate 067) nej.md/4dUqm0g
Asundexian vs. Apixaban in Atrial Fibrillation (OCEANIC-AF) nej.md/473TRdc
Vutrisiran in ATTR Amyloidosis with Cardiomyopathy (HELIOS-B) nej.md/48OTgx4